ReviewThe Lancet. Oncology2016
Neurocognitive functioning and genetic variation in patients with primary brain tumours.
Review in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review.Neuropsychology review · 2019Pooled it
- Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study.Journal of neuro-oncology · 2020Trial
- Tumor-related epilepsy and preoperative cognitive performance in glioma: a preliminary study.Journal of neuro-oncology · 2026Article
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
- Predicting late radiation-associated neurocognitive and endocrine toxicity in patients with brain tumors.Journal of neuro-oncology · 2026Article
- Cognitive Decline in Glioblastoma (GB) Patients with Different Treatment Modalities and Insights on Untreated Cases.Current oncology (Toronto, Ont.) · 2025Review
- Glioblastoma-derived migrasomes promote migration and invasion by releasing PAK4 and LAMA4.Communications biology · 2025Article
- Neuropsychological Evaluation for Oncology.Neurologic clinics · 2024Review
- The value of systemic immune inflammation index, white blood cell to platelet ratio, and homocysteine in predicting the instability of small saccular intracranial aneurysms.Scientific reports · 2024Article
- Understanding treatment preferences and cognitive outcomes in patients with gliomas.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614.International journal of radiation oncology, biology, physics · 2024Article
- Perioperative Neurocognitive Function in Glioma Surgery.Current oncology reports · 2024Review
- Executive Functions in a Patient with Low-Grade Glioma of the Central Nervous System: A Case Report.Tomography (Ann Arbor, Mich.) · 2024Article
- Glioblastoma and its treatment are associated with extensive accelerated brain aging.Aging cell · 2024Article
- Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment.Cellular & molecular immunology · 2024Article
- Neurocognitive Dysfunction After Treatment for Pediatric Brain Tumors: Subtype-Specific Findings and Proposal for Brain Network-Informed Evaluations.Neuroscience bulletin · 2023Review
- Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX.Cancer research · 2023Article
- Transcriptomic and connectomic correlates of differential spatial patterning among gliomas.Brain : a journal of neurology · 2023Article
- Initial Evidence for Positive Effects of a Psychological Preparation Program for MRI "iMReady" in Children with Neurofibromatosis Type I and Brain Tumors-How to Meet the Patients' Needs Best.Journal of clinical medicine · 2023Article
- Neuropsychological Outcomes of Children Treated for Brain Tumors.Children (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Impairment of neurocognitive functioning is a common result of cerebral neoplasms and treatment, although there is substantial heterogeneity in the pattern and severity of neurocognitive dysfunction across individuals and tumour types. The effects of many clinical and patient characteristics on neurocognitive functioning have been documented, but little research has been devoted to understanding the effect of genetic variation on neurocognitive outcomes in patients with brain tumours. This Review highlights preliminary evidence that suggests an association between various genes and risk of adverse neurocognitive outcomes in patients with brain tumours. Studies include genes specific to neuronal function, and those associated with more systemic cellular regulation. Related scientific literature in other disease populations is briefly discussed to indicate additional candidate genes. We consider methodological issues central to the study of neurocognitive functioning and genetic associations for patients with brain tumours, and emphasise the need for future research integrating novel investigative techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.